NCT01640834View on ClinicalTrials.gov

Study of LY2409021 in Participants With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

LY2409021

Administered orally

DRUG

Placebo

Administered orally

DRUG

Glucagon

Administered via intramuscular injection

Trial Locations (1)

41460

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01640834 - Study of LY2409021 in Participants With Type 1 Diabetes | Biotech Hunter | Biotech Hunter